Dr Hongnan Mo speaks to ecancer about the efficacy and safety of toripalimab and metronomic chemotherapy in HER2-negative metastatic breast cancer.

This study was a multicenter phase II trial based on a Bayesian adaptive randomised design.

This is the first clinical trial of metronomic chemotherapy combined with PD-1 blockade compared with the efficacy of combined conventional chemotherapy and immune checkpoint blockade.

The results of this study suggest promising clinical efficacy and evidence of cooperativity between metronomic VEX chemotherapy and PD-1 blockade.